- Conditions
- Breast Cancer
- Interventions
- filgrastim, amifostine trihydrate, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2023
- U.S. locations
- 1
- States / cities
- Duarte, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 793–816
of 2,369
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Essential Tremor of the Upper Limb
- Interventions
- NT 201, Placebo
- Drug
- Lead sponsor
- Merz Pharmaceuticals GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Omaha, Nebraska • Las Vegas, Nevada + 6 more
- Conditions
- Asthma
- Interventions
- AVE2635A
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Venetoclax, Azacitidine, Cytarabine, Gemtuzumab Ozogamicin, Daunorubicin Hydrochloride, Fludarabine Phosphate, Idarubicin Hydrochloride, Mitoxantrone Hydrochloride, Etoposide, Gilteritinib
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 29 Days to 21 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2034
- U.S. locations
- 10
- States / cities
- Madera, California • Orange, California • San Diego, California + 7 more
- Conditions
- Diffuse Large Cell Lymphoma Relapsed/Refractory
- Interventions
- Ofatumumab, Etoposide, Cytarabine
- Drug
- Lead sponsor
- C. Babis Andreadis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Glycemia
- Interventions
- Berberine, Dihydroberberine 200, Dihydroberberine 100, Placebo
- Dietary Supplement
- Lead sponsor
- Lindenwood University
- Other
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Alzheimer's Disease
- Interventions
- Tricaprilin, Placebo
- Drug · Other
- Lead sponsor
- Cerecin
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Cerritos, California • Los Alamitos, California + 20 more
- Conditions
- Ovarian Cancer
- Interventions
- Pembrolizumab, ALX148, Doxorubicin
- Drug
- Lead sponsor
- Alexander B Olawaiye, MD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Sickle Cell Disease, Thalassemia, Stem Cell Transplantation, Graft vs Host Disease
- Interventions
- Alemtuzumab, Sirolimus, Cyclophosphamide, Pentostatin, Radiotherapy, Filgrastim
- Drug · Procedure
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 4 Years to 80 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cardiovascular, Psychological Stress
- Interventions
- High Antioxidant Spice Blend, Trier Psychological Stressor, Placebo antioxidant concentrate
- Dietary Supplement · Behavioral · Other
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Neuroblastoma
- Interventions
- filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, mesna, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 4 more
- Conditions
- Metabolic Syndrome
- Interventions
- Blueberry Powder
- Dietary Supplement
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 20 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium Bromide, Fluticasone Propionate/Salmeterol
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 35
- States / cities
- Riverside, California • Fort Collins, Colorado • Clearwater, Florida + 31 more
- Conditions
- Glioblastoma, GBM, Glioblastoma Multiforme
- Interventions
- Ascorbate, Temozolomide, Radiation therapy
- Drug · Radiation
- Lead sponsor
- Joseph J. Cullen, MD, FACS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Obesity
- Interventions
- ascorbic acid
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 60 participants
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Chemotherapy-induced Peripheral Neuropathy (CIPN)
- Interventions
- AH-008 for Injection, 150 mg, AH-008 for Injection, Placebo
- Drug
- Lead sponsor
- AnHorn Medicines Co. Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma
- Interventions
- Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
- Biological
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Gainesville, Florida
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
- Interventions
- Mosliciguat, Dry Powder Inhaler, Placebo
- Drug · Device
- Lead sponsor
- Pulmovant, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- placebo, 0.1 mg GSK2330672, 0.3 mg GSK2330672, 1 mg GSK2330672, 3 mg GSK2330672, 10 mg GSK2330672, 30 mg GSK2330672, 60 mg GSK2330672
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Milk Allergy
- Interventions
- Placebo for omalizumab, Omalizumab, Milk powder
- Biological · Drug
- Lead sponsor
- Hugh A Sampson, MD
- Other
- Eligibility
- 7 Years to 35 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 3
- States / cities
- Stanford, California • Baltimore, Maryland • New York, New York
- Conditions
- Prediabetes
- Interventions
- Inulin, Placebo
- Dietary Supplement
- Lead sponsor
- Virginia Polytechnic Institute and State University
- Other
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Blacksburg, Virginia
- Conditions
- Non Hodgkin Lymphoma, Hodgkin Lymphoma
- Interventions
- LIFE-L Mediterranean Diet, LIFE-L Home-Based Exercise Program, Supportive Materials
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Diseases
- Interventions
- Potato-based side dish, Refined grain-based
- Dietary Supplement
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Bone and Body Composition, Obesity, Metabolic Syndrome, Physical Function, Quality of Life
- Interventions
- Whey protein isolate, Maltodextrin powder supplement
- Dietary Supplement
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 60 Years to 80 Years · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Urbana, Illinois